drugset / Trial / NCT06194201

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

NCT06194201

Phase 2 Unknown 40 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS9432 in patients with candidemia and/or invasive candidiasis

Timeline

Start
2024-04-27
Primary completion
2026-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Caspofungin Other / unclassified 50 mg Intravenous
Subject HRS9432 Unknown Intravenous

Indications